Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21047253 | 0.85 | BCHE (0.44) | BCHEALDH1A1KDM2BSMN1; SMN2ACKR3 | |
| SCHEMBL19814636 | 0.82 | KDM2B (0.51) | BCHEALDH1A1KDM2BSMN1; SMN2MEN1 | |
| SCHEMBL12225627 | 0.73 | BCHE (0.56) | BCHEALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL10202194 | 0.73 | BCHE (0.56) | BCHEALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL12225623 | 0.73 | BCHE (0.56) | BCHEALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL21047488 | 0.73 | BCHE (0.44) | BCHEALDH1A1KDM2BSMN1; SMN2ACKR3 | |
| SCHEMBL21047419 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM2BSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13654347 | 0.71 | BCHE (0.51) | BCHEALDH1A1SMN1; SMN2SYKDPP4 | |
| SCHEMBL20284509 | 0.71 | BCHE (0.51) | BCHEALDH1A1SMN1; SMN2SYKDPP4 | |
| SCHEMBL29775766 | 0.71 | BCHE (0.51) | BCHEALDH1A1SMN1; SMN2SYKDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | BCHE 4812/4885ALDH1A1 434/4885KDM2B 3060/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | BCHE 4812/4885ALDH1A1 434/4885KDM2B 3060/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | BCHE 4766/4885ALDH1A1 428/4885KDM2B 2947/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | BCHE 4766/4885ALDH1A1 428/4885KDM2B 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.